Business
Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022
ATLANTA--(BUSINESS WIRE)-- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":" ATLANTA--(BUSINESS WIRE)--\nVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference on Monday, March 14, 2022 at 10:00 a.m. PT.\n\nThe session will focus on Virios’ combination antiviral therapeutic approach, progress in advancing its pipeline, including the Phase 2b FORTRESS trial in fibromyalgia and the recently initiated collaboration in Long COVID, and upcoming milestones and value drivers.\n\nThe live and archived webcast of the session may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations.\n\nAbout Virios Therapeutics \n\nVirios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (“FM”). Immune responses related to the activation of tissue resident herpes have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (“FORTRESS”) designed to set the stage for registrational studies. Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.\n\nThe Company is pursuing a second development candidate, IMC-2 (valacyclovir and celecoxib), as a potential treatment for managing the fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID, otherwise known as Post-Acute Sequelae of COVID-19. The Company has provided Bateman Horne Center (“BHC”) with an unrestr...